Amylyx Pharmaceuticals co-CEOs Justin Klee (L) and Josh Cohen (Amylyx)

Amy­lyx’s ALS drug tastes bit­ter. What would make it bet­ter? More patent life

Amy­lyx Phar­ma­ceu­ti­cals’ ALS drug Re­lyvrio has a “be­yond aw­ful” taste, which is like “a mix­ture of salt wa­ter and Lysol,” ac­cord­ing to on­line re­views. The com­pa­ny is now work­ing on a “taste-masked” for­mu­la­tion — which can al­so po­ten­tial­ly ex­tend its patent life.

The taste-masked for­mu­la­tion “may al­low for new in­tel­lec­tu­al prop­er­ty,” per Amy­lyx’s fourth-quar­ter earn­ings re­lease. Re­lyvrio’s patent pro­tec­tions will start ex­pir­ing from 2033 with the last one set to ex­pire in 2040.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.